Form 4: Ultragenyx Director Amrit Ray Acquires Stock Options and Restricted Stock Units

Director Amrit Ray reports acquisition of stock options and restricted stock units in Ultragenyx Pharmaceutical Inc.

Summary

• On June 18, 2024, Amrit Ray, a director of Ultragenyx Pharmaceutical Inc., acquired 5,345 shares of common stock and stock options for 9,900 shares.
• The 5,345 shares were acquired through an award of Restricted Stock Units (RSUs) under the company's 2023 Incentive Plan.
• These RSUs will vest on the earlier of the company's next Annual Meeting of Stockholders or June 18, 2025.
• Ray also acquired options to purchase 9,900 shares of common stock at an exercise price of $37.42.
• These options will vest on the earlier of the company's next Annual Meeting of Stockholders or June 18, 2025.
• Following these transactions, Ray directly owns 9,900 derivative securities and 17,625 shares of Ultragenyx common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reports routine transactions. The acquisition of shares and options by a director could be interpreted as a slightly positive signal, but it's a standard part of executive compensation.

Positives

• The acquisition of stock options and restricted stock units by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting of the RSUs and stock options is contingent upon the earlier of the company's next Annual Meeting of Stockholders or June 18, 2025.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies, particularly in the pharmaceutical industry where stock-based compensation is frequently used.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as it indicates a director's investment in the company.

Key Dates